Silencing Apoe with divalent-siRNAs improves amyloid burden and activates immune response pathways in Alzheimer's disease.

Chantal M FergusonSamuel HildebrandBruno M D C GodinhoJulianna BuchwaldDimas EcheverriaAndrew ColesAnastasia GrigorenkoLorenc VangjeliJacquelyn SousaNicholas McHughMatthew HasslerFrancesco SantarelliMichael T HenekaEvgeny RogaevAnastasia Khvorova

Published in: Alzheimer's & dementia : the journal of the Alzheimer's Association (2024)

These results establish siRNA-based modulation of Apoe as a viable therapeutic approach, highlight immune activation as a key pathway affected by Apoe modulation, and provide the technology to further evaluate the impact of APOE silencing on neurodegeneration.

Keyphrases

cognitive decline
high fat diet
immune response
mild cognitive impairment
adipose tissue
risk factors
toll like receptor
drug delivery
inflammatory response
skeletal muscle